Myopia Control
Managing Myopia
Myopia management requires professional and experienced diagnosis. Trevor can effectively control progression through the use of specific medical devices and best practice patient care.
TWO uses contact lenses; Coopervision Myday or Mysight both are daliy use lenses.
Correction Zones: Keep central vision clear. Treatment Zones: Induce controlled peripheral defocus (myopic defocus), signaling the eye to slow down its elongation and prevent myopia from worsening.
Spectacle lenses supplied by Opticare (Myoease), create a similar defocus in the lenses using micro-transparent pinhole controlling the growth of the eye axis.
Myopia is typically first diagnosed in childhood. It is important to assess and diagnose myopia earlier to reduce the lifelong impact.
Trevor Williams uses highest industry technology with evidence based diagnosis and management to slow the progression of myopia.
Myopia Treatment Options
Treatments for Myopia include: Orthokeratology *totally optimised, MyoEase, MyoCare Portfolio *Zeiss, MiYOSMART *HOYA, Atropine drops *Eikance, MiSight *CooperVision, Myovision/ Myokids.
Orthokeratology
Also known as Ortho-K is a non-surgical treatment eliminating the need for spectacles and traditional contact lenses.
The process of correct fit of Ortho-K lenses requires detailed measurements for fitting to the shape of the cornea. The lessons that follow from the initial consultation, are for the correct handling, insertion and removal of these medical devices.
The wearer inserts the lenses at bedtime and removes them upon waking. The treatment works by gently reshaping your eye while you sleep. It is safe and effective in correcting nearsightedness, longsightedness, astigmatism and presbyopia.
An appointment with Dr Trevor will establish your compatibility with this innovative treatment.
Opticare MyoEase
Through digital and precise micro-engraving, the high precision micro-transparent pinholes are evenly arranged in a ring shape to form an optical defocus area.
This ring shape is integrated into the physiological curvature of the retina to slow down the growth rate of the eye axis.
ZEISS MyoCare Portfolio
The first age-related Myopia Management solution by ZEISS.
A myopia management lens design built on two pillars:
1. C.A.R.E.® technology – A patented Cylindrical Annual Refractive Elements, C.A.R.E.® technology.
2. ZEISS ClearFocus design – the optimised back surface minimises hyperopic defocus in the periphery of the lens.
The ZEISS MyoCare designs are 100% UV protected and are available in (1.59), 1.50, 1.60, and 1.67 with ZEISS DuraVision coatings.
For children aged under 10 years of age the ZEISS MyoCare design is recommended. For children aged 10 and older the ZEISS MyoCare S is appropriate.
For ZEISS, our latest lens designs for management of myopia in children is our way to say that ‘Every diopter matters and every child counts.’
HOYA MiYoSmart Lenses
Hoya MiYoSmart lenses can be used as a safe, easy to use, effective, non-invasive way to manage myopia in children. MiYoSmart lenses utilise technology which will Defocus Incorporated Multiple Segments (D.I.M.S.). MiYoSmart Lenses can slow myopia progression by 60%. ^
Using polycarbonate, impact resistant material, makes these lenses ideal for children.
UV protection
Light and thin
CooperVision MiSight® 1 Day Lenses
MiSight 1 Day lenses are single-use, child-friendly, and clinically proven to slow the progression of Myopia in children who are aged between 8-12 years old at the start of treatment.
These disposable daily lenses are not only an excellent optical treatment for children with Myopia, they also have a greater benefit than wearing regular single vision spectacles.
Features include: FDA approval, ActivControl*, child-friendly, made with a non-ionic hydrogel material with a 60% water content, and they are disposable.
There are similarities between Ortho K and MiSight. Your child’s individual suitability will be determined by Trevor during your visit.
Introducing MyDay MiSight 1 Day
MyDay MiSight 1 day wityh ActivControl Technology is indicated for the correction of ametropia (myopia) and slowing the progression of myopia.
ActivControl Technology
ActivControl Technology is supported by 7 years of clinical evidence from. the longest running soft contact lens study among children.
Atropine
